Compare FFWM & DNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FFWM | DNA |
|---|---|---|
| Founded | 1990 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 510.6M | 562.3M |
| IPO Year | 2014 | N/A |
| Metric | FFWM | DNA |
|---|---|---|
| Price | $6.30 | $9.11 |
| Analyst Decision | Buy | Strong Sell |
| Analyst Count | 3 | 1 |
| Target Price | $6.17 | ★ $9.00 |
| AVG Volume (30 Days) | 514.1K | ★ 1.0M |
| Earning Date | 01-29-2026 | 02-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $159,621,000.00 | ★ $180,606,000.00 |
| Revenue This Year | $166.48 | N/A |
| Revenue Next Year | $6.86 | $7.28 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 47.55 | N/A |
| 52 Week Low | $4.42 | $5.00 |
| 52 Week High | $6.47 | $17.58 |
| Indicator | FFWM | DNA |
|---|---|---|
| Relative Strength Index (RSI) | 65.50 | 51.86 |
| Support Level | $6.01 | $8.08 |
| Resistance Level | $6.29 | $9.75 |
| Average True Range (ATR) | 0.16 | 0.50 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 72.04 | 61.68 |
First Foundation Inc is a financial services company. It is engaged in providing investment management and financial planning services for high-net-worth individuals, retirement plans, charitable institutions, and private foundations. The company focuses on segments namely Banking and Wealth Management. It also offers loans to individuals and entities that own and operate multifamily residential and commercial real estate properties as well as business banking products and services to small to moderate-sized businesses, professional firms, and consumer banking products and services to individuals.
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.